This suggests that although futibatinib is pharmacodynamically active in suppressing FGFR4 signaling in the tumor, it is ineffective as a monotherapy for RMS, possibly due to adaptive resistance mechanisms to FGFR4 inhibition. The gene discussed is FGFR4; the disease is neoplasm.